Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04214626
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 13
- Registration Number
- NCT04196491
- Locations
- 🇺🇸
Local Institution - 117, Hackensack, New Jersey, United States
🇺🇸Local Institution - 108, Atlanta, Georgia, United States
🇺🇸Local Institution - 110, Los Angeles, California, United States
A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT04174196
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 57
- Registration Number
- NCT04140162
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Texas Southwestern -- Simmons Comprehensive Cancer Center, Dallas, Texas, United States
🇺🇸University of Rochester, Rochester, New York, United States
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 237
- Registration Number
- NCT04133636
- Locations
- 🇺🇸
Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia, United States
🇺🇸University Of California San Diego, San Diego, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2021-07-16
- Target Recruit Count
- 120
- Registration Number
- NCT04129710
- Locations
- 🇨🇳
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China/Zhejiang Province, China
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 464
- Registration Number
- NCT04126200
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty
- Conditions
- Interventions
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2020-06-05
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT04120350
- Locations
- 🇨🇳
Daobin Zhou, Beijing, Dongcheng District, China
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
- Conditions
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Beijing Mabworks Biotech Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT04110301
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.
- Conditions
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2020-02-05
- Target Recruit Count
- 25
- Registration Number
- NCT04109872
- Locations
- 🇪🇸
Hospital Universitario Virgen Macarena, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.